Sulkowski Mark S, Thomas David L
Division of Infections Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 448, Baltimore, MD 21287-0003, USA.
Ann Intern Med. 2003 Feb 4;138(3):197-207. doi: 10.7326/0003-4819-138-3-200302040-00012.
Because of shared routes of transmission, hepatitis C virus (HCV) infection is common in HIV-infected persons, who have been experiencing increasing HCV-related morbidity and mortality since the advent of effective antiretroviral therapy. Infection with HIV appears to adversely affect the outcome of hepatitis C, leading to increased viral persistence after acute infection, higher levels of viremia, and accelerated progression of HCV-related liver disease. In addition, hepatitis C may affect the course and management of HIV infection. The medical management of hepatitis C in HIV-infected persons is complicated by immune suppression, potential drug interactions and toxicities, and other forms of liver disease. In addition, there is little published experience with the safety and efficacy of the best available anti-HCV medications in HIV-infected persons. Thus, current efforts must be directed at preventing HCV and HIV infections and applying the principles learned in treating persons with either infection to manage those with both. Future efforts should include studies of the pathogenesis of HCV infection in HIV-infected persons and large, prospective studies that demonstrate the optimal management of persons co-infected with HIV and HCV. Such efforts will help to eliminate HCV-related liver disease as an emerging threat to HIV-infected persons.
由于传播途径相同,丙型肝炎病毒(HCV)感染在HIV感染者中很常见,自有效抗逆转录病毒治疗出现以来,HIV感染者中与HCV相关的发病率和死亡率一直在上升。感染HIV似乎会对丙型肝炎的病情产生不利影响,导致急性感染后病毒持续存在增加、病毒血症水平升高以及HCV相关肝病进展加速。此外,丙型肝炎可能会影响HIV感染的病程和管理。HIV感染者丙型肝炎的药物治疗因免疫抑制、潜在的药物相互作用和毒性以及其他形式的肝病而变得复杂。此外,关于现有最佳抗HCV药物在HIV感染者中的安全性和有效性的公开经验很少。因此,当前的努力必须致力于预防HCV和HIV感染,并运用在治疗单一感染患者中获得的原则来管理同时感染两种病毒的患者。未来的努力应包括对HIV感染者中HCV感染发病机制的研究,以及大型前瞻性研究,以证明对HIV和HCV合并感染患者的最佳管理方法。这些努力将有助于消除HCV相关肝病这一对HIV感染者新出现的威胁。